Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2016 06:43 ET | Source: BioPorto A/S

Jan Kuhlmann Andersen new COO in BioPorto A/S - resigns from the company's board

Jan Kuhlmann Andersen, Ph.D., M.Sc. Biology/Immunology, joins BioPorto A/S (BioPorto) on September 12, 2016 as Chief Operation Officer (COO). As a consequence and on the same date, he will retire...
August 08, 2016 06:43 ET | Source: BioPorto A/S

Jan Kuhlmann Andersen ny COO i BioPorto A/S – udtræder af selskabets bestyrelse

Jan Kuhlmann Andersen, Ph.d, M.Sc. Biologi/Immunologi, tiltræder den 12. september 2016 som Chief Operation Officer (COO) i BioPorto A/S (BioPorto). Som konsekvens heraf udtræder han samme dato af...
August 04, 2016 02:57 ET | Source: BioPorto A/S

Interim report, first half of 2016

New process for US approval of The NGAL Test™ initiated after rejection In May 2016, BioPorto received notification that the FDA had rejected the company’s application for approval of The NGAL...
August 04, 2016 02:57 ET | Source: BioPorto A/S

Kvartalsrapport for 1. halvår 2016

Ny proces for amerikansk godkendelse af The NGAL TestTM iværksat efter afslag BioPorto modtog i maj 2016 besked om, at de amerikanske sundhedsmyndigheder, FDA, havde afvist selskabets...
July 05, 2016 12:58 ET | Source: BioPorto A/S

BioPorto’s NGAL Exclusion patent is ruled invalid by the EPO – BioPorto to appeal decision

Today, the European Patent Office (EPO) has ruled in the opposition case againts BioPorto’s BioPorto's NGAL Exclusion patent no. EP 2064553. The EPO ruled the patent invalid. The decision is a...
July 05, 2016 12:58 ET | Source: BioPorto A/S

EPO kender BioPortos NGAL eksklusionspatent ugyldigt – BioPorto anker sagen

De europæiske patentmyndigheder (EPO) har i dag truffet afgørelse i indsigelsessagen mod BioPortos NGAL eksklusionspatent nr. EP 2064553. EPO har afgjort, at patentet er ugyldigt. Afgørelsen er en...
July 04, 2016 05:53 ET | Source: BioPorto A/S

BioPorto beslutter at genansøge om FDA godkendelse af The NGAL TestTM

BioPorto A/S (BioPorto) har besluttet at genansøge om godkendelse af selskabets nyreskadetest, The NGAL TestTM, hos de amerikanske sundhedsmyndigheder, FDA. Beslutningen kommer i forlængelse af en...
July 04, 2016 05:53 ET | Source: BioPorto A/S

BioPorto decides to reapply for FDA approval of The NGAL TestTM

BioPorto A/S (BioPorto) has decided to reapply for approval of the Company’s kidney injury test, The NGAL Test™, with the Food and Drug Administration (FDA) in USA. The decision follows a positive...
June 06, 2016 16:50 ET | Source: BioPorto A/S

Clinical Leaders Reinforce Belief in NGAL for Detection of AKI Following FDA’s Decision on BioPorto’s The NGAL TestTM

Copenhagen, 2016-06-06 22:50 CEST (GLOBE NEWSWIRE) -- In response to the recent FDA decision to decline BioPorto’s initial submission for the kidney biomarker neutrophil gelatinase-associated...
June 06, 2016 16:50 ET | Source: BioPorto A/S

Ledende kliniske eksperter bekræfter deres tro på NGAL i diagnostik af akut nyreskade efter FDAs beslutning om BioPorto’s The NGAL TestTM

København, 2016-06-06 22:50 CEST (GLOBE NEWSWIRE) -- Som reaktion på sidste uges beslutning fra den amerikanske registreringsmyndighed, FDA, har flere ledende amerikanske kliniske eksperter, på...